Закажите звонок



Ваша заявка успешно отправлена. В ближайшее время с Вами свяжется наш специалист.

List of publications for


European Science Review, Issue 9-10/2016

Efficacy and safety of highly active antiretroviral therapy comprising tenofovir in patients with HIV infection

DOI: https://doi.org/10.29013/ESR-16-9.10-79-81

Pages: 79 - 81

Authors: Bayjanov A. K.

Abstract: The objective of the study was to evaluate the effectiveness and safety of highly active antiretroviral therapy regimens containing tenofovir — TDF in HIV patients. Three classes of antiretroviral agents today are commonly used for the specific treatment of patients with HIV: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors (1, 5, 7). The other drugs of the same class — nucleoside reverse transcriptase inhibitors — were developed in the following years (3, 4). One of the current nucleoside reverse transcriptase inhibitor is Tenofovir (2). Inclusion of Tenofovir drug into antiretroviral therapies leads to suppression of the replicative capacity of human immunodeficiency virus. The nucleoside inhibitors bind stronger to reverse transcriptase than to host cell DNA polymerases. This provides them with a relatively selective effect on the virus. The drug Tenofovir (TDF) in 2001 was approved for use as part of antiretroviral therapy (ART) for the treatment of patients with HIV infection (6).

Keywords: antiretroviral therapy, tenofovir, viral load, nucleotide and non-nucleoside reverse transcriptase inhibitor

1. Bushman F. D., Nabel G. J., Swanstrom R. HIV: From biology to prevention and treatment. – Cold Spring Harbor, New York, USA:
Cold Spring Harbor Laboratory Press, – 2012. – Р. 321–343.
2. Daar E., Tierney C., Fischl M. et al. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive
HIV-infected patients. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. February, 16–19.
2010. San Francisco, California. Abstract, – 59 LB.
3. Hall J. C., Hall B. J., Cockerell C. J. HIV/AIDS in the post-HAART era: Manifestations, treatment, and epidemiology. – Shelton, CT,
USA: People’s Medical Publishing House – USA, 2011. – Р. 389–403.
4. McComsey G., Kitch D., Daar E. et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective,
randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV‑1 infection.
Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. February, – 16–19. – 2010. San Francisco.
Abstract 106 LB.
5. Saag M. S., Chambers H. F., Eliopoulos G. M., Gilbert D. N., Moellering R. C. The Sanford guide to HIV/AIDS therapy 2012. – Sperryville,
VA, USA: Antimicrobial Therapy Inc., – 2012. – Р. 214.
6. Shafer R. W., Schapiro J. M. Drug resistance and antiretroviral drug development in patients with HIV infection//J. Antimicrob. Chemother.
– 2005. – Vol. 55. – P. 817–820.
7. Volberding P. A., Greene W. C., Lange J. M. A., Gallant J. E., Sewankambo N. Sande’s HIV/AIDS medicine: Medical management of
AIDS – 2013. – Elsevier. – P. 133–191.